Organon & Co. (NYSE:OGN – Get Free Report) and Finch Therapeutics Group (NASDAQ:FNCH – Get Free Report) are both healthcare companies, but which is the better business? Analyst RatingsThis is a breakdown of current ratings for Organon & Co. and Finch Therapeutics Group, as provided by MarketBeat. Given Organon & Co.’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Organon & Co. is more favorable than Finch Therapeutics Group. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Organon & Co. $6.13 billion 0.59 $187.00 million $0.77 17.74 Finch Therapeutics Group N/A N/A -$74.75 million ($8.82) -0.83Organon & Co. has higher revenue and earnings than Finch Therapeutics Group. About Finch Therapeutics Group(Get Free Report)Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States.